The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 19, 2021

Filed:

Jan. 12, 2017
Applicant:

Sitokine Limited, London, GB;

Inventors:

Lynn Doucette-Stamm, Framingham, MA (US);

Gordon W. Duff, Sheffield, GB;

Kenneth S. Kornman, Newton, MA (US);

Assignee:

Sitokine Limited, London, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); G16B 30/00 (2019.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); A61K 9/0048 (2013.01); A61K 38/16 (2013.01); G16B 30/00 (2019.02); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/172 (2013.01);
Abstract

The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a 'high' or 'low' producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.


Find Patent Forward Citations

Loading…